Literature DB >> 3350235

A versatile method for simultaneous analysis of families of curves.

V Guardabasso1, P J Munson, D Rodbard.   

Abstract

We have developed a versatile new approach to the simultaneous analysis of families of curves, which combines the simplicity of empirical methods with several of the advantages of mathematical modeling, including objective comparison of curves and statistical hypothesis testing. The method uses weighted smoothing cubic splines; the degree of smoothing is adjusted automatically to satisfy constraints on curve chape (monotonicity, number of inflection points). By simultaneous analysis of a family of curves, one can extract the shape common to all the curves. Up to four linear scaling parameters are used to match the shape to each curve, and to provide optimal superimposition of the several curves. By applying constraints to these scaling factors, one can test a variety of hypotheses concerning comparisons of curves (e.g., identity, parallelism, or similarity of shape of two or more curves), and thus evaluate the effects of experimental manipulation. By optimal pooling of data one can avoid the need for arbitrary selection of a typical experiment, and can detect subtle but reproducible effects that might otherwise be overlooked. This approach can facilitate the development of an appropriate model. The method has been implemented in a Turbo-Pascal program for IBM-PC compatible microcomputers, and in FORTRAN-77 for the DEC-10 mainframe, and has been utilized successfully in a wide variety of applications.

Mesh:

Year:  1988        PMID: 3350235     DOI: 10.1096/fasebj.2.3.3350235

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  11 in total

1.  A(2A) adenosine receptor mediated potassium channel activation in rat epididymal smooth muscle.

Authors:  J M Haynes
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

2.  Parameterizing dose-response models to estimate relative potency functions directly.

Authors:  Gregg E Dinse; David M Umbach
Journal:  Toxicol Sci       Date:  2012-06-14       Impact factor: 4.849

3.  Alpha-adrenoceptor mediated responses of the cauda epididymis of the guinea-pig.

Authors:  J M Haynes; S J Hill
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

4.  Determination of parallelism and nonparallelism in bioassay dilution curves.

Authors:  B D Plikaytis; P F Holder; L B Pais; S E Maslanka; L L Gheesling; G M Carlone
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

5.  The P2Z-purinoceptor of human lymphocytes: actions of nucleotide agonists and irreversible inhibition by oxidized ATP.

Authors:  J S Wiley; J R Chen; M B Snook; G P Jamieson
Journal:  Br J Pharmacol       Date:  1994-07       Impact factor: 8.739

6.  Characterizing non-constant relative potency.

Authors:  Gregg E Dinse; David M Umbach
Journal:  Regul Toxicol Pharmacol       Date:  2011-05-13       Impact factor: 3.271

7.  Gi-Protein alpha-subunit mRNA antisense oligonucleotide inhibition of Gi-coupled receptor contractile activity in the epididymis of the guinea-pig.

Authors:  J M Haynes; L A Selbie; S J Hill
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

8.  Neo-osteogenesis of haversian trabeculae through a bone chamber implanted in a rabbit tibial cortex: a control model.

Authors:  H Winet; J Y Bao; R Moffat
Journal:  Calcif Tissue Int       Date:  1990-07       Impact factor: 4.333

9.  Comparisons of standard curve-fitting methods to quantitate Neisseria meningitidis group A polysaccharide antibody levels by enzyme-linked immunosorbent assay.

Authors:  B D Plikaytis; S H Turner; L L Gheesling; G M Carlone
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

10.  Blockade by polyamine NMDA antagonists related to ifenprodil of NMDA-induced synthesis of cyclic GMP, increases in calcium and cytotoxicity in cultured neurones.

Authors:  P M Beart; A Schousboe; A Frandsen
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.